Voutsas IF - Search Results

1

Aldehyde Dehydrogenase Enzyme Functions in Acute Leukemia Stem Cells.

Dancik GM, Voutsas IF, Vlahopoulos S. Dancik GM, et al. Among authors: voutsas if. Front Biosci (Schol Ed). 2022 Mar 8;14(1):8. doi: 10.31083/j.fbs1401008. Front Biosci (Schol Ed). 2022. PMID: 35320919 Free article. Review.

2

New use for old drugs? Prospective targets of chloroquines in cancer therapy.

Vlahopoulos S, Critselis E, Voutsas IF, Perez SA, Moschovi M, Baxevanis CN, Chrousos GP. Vlahopoulos S, et al. Among authors: voutsas if. Curr Drug Targets. 2014;15(9):843-51. doi: 10.2174/1389450115666140714121514. Curr Drug Targets. 2014. PMID: 25023646 Review.

3

Lower RNA expression of ALDH1A1 distinguishes the favorable risk group in acute myeloid leukemia.

Dancik GM, Voutsas IF, Vlahopoulos S. Dancik GM, et al. Among authors: voutsas if. Mol Biol Rep. 2022 Apr;49(4):3321-3331. doi: 10.1007/s11033-021-07073-7. Epub 2022 Jan 14. Mol Biol Rep. 2022. PMID: 35028852 Review.

4

Editorial: Acute leukemias: molecular characterization, leukemia-initiating cells, and influence of the microenvironment.

Dancik GM, Varisli L, Voutsas IF, Vlahopoulos S. Dancik GM, et al. Among authors: voutsas if. Front Oncol. 2023 May 10;13:1199354. doi: 10.3389/fonc.2023.1199354. eCollection 2023. Front Oncol. 2023. PMID: 37234979 Free PMC article. No abstract available.

5

T-Cell Repertoire in Tumor Radiation: The Emerging Frontier as a Radiotherapy Biomarker.

Baxevanis CN, Gritzapis AD, Voutsas IF, Batsaki P, Goulielmaki M, Adamaki M, Zoumpourlis V, Fortis SP. Baxevanis CN, et al. Among authors: voutsas if. Cancers (Basel). 2022 May 27;14(11):2674. doi: 10.3390/cancers14112674. Cancers (Basel). 2022. PMID: 35681654 Free PMC article. Review.

6

The prognostic value of alpha-thymosins in breast cancer.

Tsitsilonis OE, Bekris E, Voutsas IF, Baxevanis CN, Markopoulos C, Papadopoulou SA, Kontzoglou K, Stoeva S, Gogas J, Voelter W, Papamichail M. Tsitsilonis OE, et al. Among authors: voutsas if. Anticancer Res. 1998 May-Jun;18(3A):1501-8. Anticancer Res. 1998. PMID: 9673361

7

Mistletoe lectin I-induced effects on human cytotoxic lymphocytes. I. Synergism with IL-2 in the induction of enhanced LAK cytotoxicity.

Baxevanis CN, Voutsas IF, Soler MH, Gritzapis AD, Tsitsilonis OE, Stoeva S, Voelter W, Arsenis P, Papamichail M. Baxevanis CN, et al. Among authors: voutsas if. Immunopharmacol Immunotoxicol. 1998 Aug;20(3):355-72. doi: 10.3109/08923979809034819. Immunopharmacol Immunotoxicol. 1998. PMID: 9736441

8

Increased generation of autologous tumor-reactive lymphocytes by anti-CD3 monoclonal antibody and prothymosin alpha.

Baxevanis CN, Spanakos G, Voutsas IF, Gritzapis AD, Tsitsilonis OE, Mamalaki A, Papamichail M. Baxevanis CN, et al. Among authors: voutsas if. Cancer Immunol Immunother. 1999 May-Jun;48(2-3):71-84. doi: 10.1007/s002620050550. Cancer Immunol Immunother. 1999. PMID: 10414460 Free PMC article.

9

Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor.

Baxevanis CN, Voutsas IF, Tsitsilonis OE, Gritzapis AD, Sotiriadou R, Papamichail M. Baxevanis CN, et al. Among authors: voutsas if. J Immunol. 2000 Apr 1;164(7):3902-12. doi: 10.4049/jimmunol.164.7.3902. J Immunol. 2000. PMID: 10725753

10

Compromised anti-tumor responses in tumor necrosis factor-alpha knockout mice.

Baxevanis CN, Voutsas IF, Tsitsilonis OE, Tsiatas ML, Gritzapis AD, Papamichail M. Baxevanis CN, et al. Among authors: voutsas if. Eur J Immunol. 2000 Jul;30(7):1957-66. doi: 10.1002/1521-4141(200007)30:7<1957::AID-IMMU1957>3.0.CO;2-7. Eur J Immunol. 2000. PMID: 10940885 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

36 results

Search Page